Creo Medical Group (LON:CREO) Given “House Stock” Rating at Shore Capital Group

Creo Medical Group (LON:CREO)‘s stock had its “house stock” rating reissued by stock analysts at Shore Capital Group in a research note issued on Monday,Digital Look reports. They currently have a GBX 40 price objective on the stock. Shore Capital Group’s price target would indicate a potential upside of 174.73% from the company’s previous close.

Creo Medical Group Trading Up 6.7%

Shares of CREO stock opened at GBX 14.56 on Monday. The stock has a market cap of £70.73 million, a P/E ratio of 14.56 and a beta of 1.62. Creo Medical Group has a 1 year low of GBX 9.52 and a 1 year high of GBX 18.50. The company has a current ratio of 3.22, a quick ratio of 2.19 and a debt-to-equity ratio of 8.20. The stock has a 50 day simple moving average of GBX 13.02 and a 200 day simple moving average of GBX 12.75.

Creo Medical Group (LON:CREO) last posted its quarterly earnings data on Friday, May 22nd. The company reported GBX (0.04) EPS for the quarter. The company had revenue of GBX 600 million for the quarter. Creo Medical Group had a return on equity of 9.56% and a net margin of 88.33%. On average, research analysts predict that Creo Medical Group will post -10.0800005 earnings per share for the current fiscal year.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.